MXPA03000931A - Composiciones y metodos para el tratamientos de trastornos anorectales. - Google Patents

Composiciones y metodos para el tratamientos de trastornos anorectales.

Info

Publication number
MXPA03000931A
MXPA03000931A MXPA03000931A MXPA03000931A MXPA03000931A MX PA03000931 A MXPA03000931 A MX PA03000931A MX PA03000931 A MXPA03000931 A MX PA03000931A MX PA03000931 A MXPA03000931 A MX PA03000931A MX PA03000931 A MXPA03000931 A MX PA03000931A
Authority
MX
Mexico
Prior art keywords
compositions
treatment
methods
anorectal disorders
activators
Prior art date
Application number
MXPA03000931A
Other languages
English (en)
Inventor
Charles Lee
Original Assignee
Cellegy Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellegy Pharma Inc filed Critical Cellegy Pharma Inc
Publication of MXPA03000931A publication Critical patent/MXPA03000931A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Abstract

Se proporcionan composiciones y metodos para el tratamiento de trastornos anorectales en los cuales se utilizan ciertas combinaciones de donadors NO, inhibidores de PDE, captores de superoxido (O2-), agonistas ??-adrenergicos, activadores de protein cinasa dependientes de cAMP, antagonistas a1-adrenergicos, bloqueadores del canal Ca2+ tipo L, estrogenos, activadores del canal K+ sensibles a ATP y relajantes del musculo liso.
MXPA03000931A 2000-07-31 2001-07-30 Composiciones y metodos para el tratamientos de trastornos anorectales. MXPA03000931A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22226700P 2000-07-31 2000-07-31
PCT/US2001/023971 WO2002009714A1 (en) 2000-07-31 2001-07-30 Compositions and methods for the treatment of anorectal disorders

Publications (1)

Publication Number Publication Date
MXPA03000931A true MXPA03000931A (es) 2004-08-12

Family

ID=22831555

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03000931A MXPA03000931A (es) 2000-07-31 2001-07-30 Composiciones y metodos para el tratamientos de trastornos anorectales.

Country Status (8)

Country Link
EP (1) EP1315499A4 (es)
JP (1) JP2004516244A (es)
KR (3) KR100863758B1 (es)
AU (1) AU2001279104A1 (es)
CA (1) CA2417848A1 (es)
IL (1) IL154202A0 (es)
MX (1) MXPA03000931A (es)
WO (1) WO2002009714A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0020588D0 (en) * 2000-08-21 2000-10-11 Pfizer Ltd Treatment of wounds
US8987245B2 (en) 2008-04-02 2015-03-24 Jonathan R. Brestoff Parker Composition and method for affecting obesity and related conditions
US8598150B1 (en) 2008-04-02 2013-12-03 Jonathan R. Brestoff Composition and method for affecting obesity and related conditions
KR101067443B1 (ko) 2009-06-23 2011-09-27 여오영 하이드록시클로로퀸을 함유하는 치핵 치료를 위한 국소투여용 주사제 조성물
CN102145004B (zh) * 2010-02-09 2012-03-21 鲁南制药集团股份有限公司 己酮可可碱在制备预防或治疗功能性便秘的药物中的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595753A (en) 1995-04-14 1997-01-21 President And Fellows Of Harvard College Topical formulations and methods for treating hemorrhoidal pain and sphincter and smooth muscle spasm in the gastrointestinal tract
JP4489289B2 (ja) * 1998-02-27 2010-06-23 シンクロニュ−ロン，エルエルシ− 肛門部の痛みのある状態を治療するための方法及びそのための組成物
JP2002542147A (ja) * 1998-12-14 2002-12-10 セレジィ ファーマシューティカルス， インコーポレイテッド 肛門直腸障害の処置のための組成物および方法

Also Published As

Publication number Publication date
KR20080068145A (ko) 2008-07-22
AU2001279104A1 (en) 2002-02-13
IL154202A0 (en) 2003-07-31
KR20030024826A (ko) 2003-03-26
KR20100017750A (ko) 2010-02-16
EP1315499A1 (en) 2003-06-04
WO2002009714A9 (en) 2003-03-06
JP2004516244A (ja) 2004-06-03
EP1315499A4 (en) 2007-09-05
KR100863758B1 (ko) 2008-10-16
CA2417848A1 (en) 2002-02-07
WO2002009714A1 (en) 2002-02-07

Similar Documents

Publication Publication Date Title
WO2000035434A3 (en) Compositions and methods for the treatment of anorectal disorders
HUP0202682A3 (en) Tyrosine kinase inhibitors, pharmaceutical compositions containing them and their use
HUP0200355A3 (en) 4-aminopyrrolopyrimidines as kinase inhibitors, pharmaceutical compositions containing them and their use
HUP0103633A2 (hu) Szubsztituált 3-cianokinolinok mint protein tirozin kinázok inhibitorai, eljárás a vegyületek előállítására és a vegyületeket tartalmazó gyógyászati készítmények
AP2002002621A0 (en) Pharmaceutical compositions of glycogen phosphorylase inhibitors
HUP0104752A3 (en) Quinoline and quinoxaline compounds as pdgf-r and/or lck tyrosine kinase inhibitors and pharmaceutical compositions containing them
HUP0103520A3 (en) Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors and pharmaceutical compositions containing them
IL125735A (en) Pharmaceutical compositions for the treatment of glaucoma comprising an inhibitor of serine-threonine kinase, tyrosine kinase or protein tyrosine phosphatase or an actin-disrupting compound
HUP0400908A3 (en) Pyrazole compounds useful as protein kinase inhibitors, their use and pharmaceutical compositions containing them
HUP0200403A2 (en) Pyrrolopyrimidines as protein kinase inhibitors, pharmaceutical compositions containing them and their use
BRPI0418112A (pt) inibidores de p-38 quinase bicìclico heterocìclicos
HUP0300741A3 (en) Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
DK1347971T3 (da) Thiazolylinhibitorer af tyrosinkinaser fra Tec-familien
HUP0402454A3 (en) Substituted quinazoline derivatives as inhibitors of aurora kinases, process for their preparation and pharmaceutical compositions containing them
MXPA02005844A (es) Inhibidores de cinasas de proteina.
HUP0203477A3 (en) Alkylamino substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase, pharmaceutical compositions containing them and their preparations
WO2004085388A3 (en) Cyclic protein tyrosine kinase inhibitors
HUP0301117A3 (en) Imidazole derivatives kinase inhibitors, their use, process for their preparation and pharmaceutical compositions containing them
IL175568A (en) Tyrosine kinase inhibitors, containing them containing herbal remedies and their use in the preparation of a drug for the treatment of diseases
AU2002313249A1 (en) Quinoline derivative and quinazoline derivate inhibiting self-phosphorylation of hepatocytus proliferator receptor, and medicinal composition containing the same
IL152316A0 (en) Pharmaceutical compositions and kits for treating transplant rejection
AR024138A1 (es) Inhibidores de la proliferacion celular
WO2003002114A3 (en) Use of potent, selective and non toxic c-kit inhibitors for treating mastocytosis
PL364359A1 (en) Treatment or prophylaxis of insulin-producing cell graft rejection
CA2378428A1 (en) Use of cgrp antagonists and cgrp release inhibitors for combating menopausal hot flushes